Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.

Tirapazamine (SR 4233), a bioreductive drug selectively toxic towards hypoxic cells, is presently in phase II clinical trials. Since it would not be expected that all tumours would respond equally to the drug, we are exploring ways of predicting the response of individual tumours. In this study we h...

Descripción completa

Detalles Bibliográficos
Autores principales: Siim, B. G., van Zijl, P. L., Brown, J. M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075810/
https://www.ncbi.nlm.nih.gov/pubmed/8611431

Ejemplares similares

Ejemplares similares